Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases**
References (30)
- et al.
Preparation of 186-rhenium labelled HEDP and its possible use in the treatment of osseous neoplasms
Int J Appl Radiat Isot
(1979) Preparation of Re-186 perrhenate for nuclear medical purposes
Int J Appl Radiat Isot
(1982)- et al.
The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine
Int J Nucl Med Biol
(1986) - et al.
Effect of pH on the formation of Tc(NaBH4)-MDP radiopharmaceutical analogues
Int J Appl Radiat Isotope
(1983) - et al.
The effect of formulation conditions on the distribution of 99m-Tc(NaBH4)-HEDP components separated by anion exchange HPLC. Part A
Int J Appl Radiat Isot
(1986) - et al.
In vivo distributions of some component fractions of Tc(NaBH4)-HEDP mixtures separated by anion exchange high performance liquid chromatography
Int J Appl Radiat Isot
(1982) - et al.
The biological distribution of some technetium-MDP components isolated by anion exchange high performance liquid chromatography
Int J Appl Radiat Isot
(1983) - et al.
HPLC separated fractions of 99m-Tc(NaBH4)-HEDP as myocardial infarct imaging agents. Part A
Int J Appl Radiat Isot
(1986) - et al.
The palliation of symptomatic osseous metastases: Final results of the study by the Radiation Therapy Oncology Group
Cancer
(1982) - et al.
Single dose half-body irradiation for palliation of multiple bone metastases from solid tumors: Final Radiation Therapy Oncology Group report
Cancer
(1986)
Bone radiopharmaceuticals
Comparison of the chemical and biological properties of trans-[Tc(DMPE)2Cl2]+ and trans-[Re(DMPE)2Cl2]+, where DMPE=1,2-Bis (dimethylphosphine)ethane: Single-crystal structural analysis of trans-[Re(DMPE)2Cl2]PF6
Inorganic Chem
Separation of technetium hydroxyethylidene diphosphonate complexes by anion-exchange high performance liquid chromatography
Anal Chem
Re-186-HEDP: A potential therapeutic bone agent
J Nucl Med
Re-186(Sn)HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies
Radiology
Cited by (108)
Dosimetry of Bone Seeking Beta Emitters for Bone Pain Palliation Metastases
2022, Seminars in Nuclear MedicineCitation Excerpt :Along with uptake in bone tissue, the biodistribution of 186Re-HEDP involves rapid urinary excretion and rapid blood clearance with a plasma half-life of 41 hours, similar to 99mTc-HMDP. Gamma-camera imaging of 186Re-HEDP and 99mTc-HMDP has demonstrated showed excellent correlation, with 89 % of lesions being detected in both85 Maxon et al 34 performed dosimetry in five patients. Absorbed doses were determined in numerous source and target organs: kidney, bladder wall, skeleton, whole body, red bone marrow and bone metastases.
Organometallic and coordination rhenium compounds and their potential in cancer therapy
2019, Coordination Chemistry ReviewsCitation Excerpt :However, bisphosphonates are a prominent class of Re/Tc radiopharmaceuticals, which are currently used in the clinic and thus should be mentioned in this review. These compounds have been known to target bone cancer/metastases for over 30 years and clinical trials are ongoing [175–181]. Specifically, a clinical trial initiated in spring 2018 is currently recruiting patients and involve a combination of 223Ra chloride and 188Re-HEDP treatment.
Evaluation of production cross-sections for <sup>186</sup>Re theranostic radionuclide via charged-particle induced reactions on Tungsten
2018, Applied Radiation and IsotopesMetastatic Disease: Bone, Spinal Cord, Brain, Liver, and Lung
2015, Clinical Radiation OncologyModeling the time dependent biodistribution of Samarium-153 ethylenediamine tetramethylene phosphonate using compartmental analysis
2014, Reports of Practical Oncology and RadiotherapyCitation Excerpt :Systemic therapy with radionuclides linked to bone seeking agents is a treatment option for patients with disseminated skeletal metastases, owing to its efficacy, low cost and low toxicity.12 Radionuclides suitable for systemic metabolic radiotherapy of bone pain include Phosphorous-32 (P-32), Strontium-89 (Sr-89), Rhenium-186 (Re-186) chelated with hydroxyethylidene diphosphonate (HEDP) and Samariumm-153 (Sm-153) chelated with ethylenediamine tetramethylene phosphonate (EDTMP).13–16 Considerable bone marrow suppression due to the presence of higher energy β particles is a major constraint toward a widespread use of P-32 (mean β = 695 keV, t1/2 = 14.3 days) and Sr-89 (mean β = 583 keV, t1/2 = 50.5 days).
Metastatic Disease: Bone, Spinal Cord, Brain, Liver, and Lung. Bone, Spinal Cord, Brain, Liver, and Lung.
2012, Clinical Radiation Oncology: Third Edition
- **
Supported by grants from the National Cancer Institute, National Institutes of Health (CA-32863) and General Clinical Research Center (MO1-RR00068), and through the University Reactor Sharing Program of the Department of Energy for the production of rhenium-186 by the University of Missouri Research Reactor Facility, Columbia, MO.